PLCXD2-AS1

Across TCGA pan-cancer cohorts, PLCXD2-AS1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated PLCXD2-AS1 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher PLCXD2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCXD2-AS1 expression acts as an unfavorable survival marker, although some lineages such as COAD and SKCM show a favorable association.

UVM, ACC, and LIHC are the cancer types where PLCXD2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	All	0.079	0.746	<.001	54	view →
ACC	DFS	Tertile	II,III,IV	0.010	0.582	<.001	45	view →
LIHC	OS	Tertile	All	0.658	0.803	.003	39	view →
LUSC	DFS	Tertile	III,IV	0.330	0.951	.003	35	view →
MESO	OS	Median	All	0.240	0.721	<.001	35	view →
KICH	DFS	Tertile	III,IV	0.266	0.885	.005	23	view →
DLBC	DFS	Tertile	All	0.470	0.879	.006	21	view →
COAD	OS	Median	II,III,IV	0.858	0.707	.014	16	view →
PAAD	OS	Median	III,IV	0.629	1.000	.022	12	view →
TGCT	DFS	Tertile	III,IV	0.604	1.000	.044	12	view →
LGG	OS	Tertile	All	0.282	0.544	.007	12	view →
SKCM	OS	Quartile	All	0.459	0.298	.007	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

PLCXD2-AS1–UVM (DFS)

Open the UVM breakdown →